Published in Nature on October 25, 1990
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol (2003) 3.34
Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet (1997) 3.08
CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer (2009) 2.32
Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med (2007) 2.02
Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J (1992) 1.44
Pharmacogenetic profile of xenobiotic enzyme metabolism in survivors of the Spanish toxic oil syndrome. Environ Health Perspect (2001) 1.41
The human glutathione S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer. Environ Health Perspect (1992) 1.26
Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol (2011) 1.17
Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Eur J Clin Pharmacol (2006) 1.13
Tramadol extended-release in the management of chronic pain. Ther Clin Risk Manag (2007) 1.05
Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab (2011) 0.99
Carcinogen metabolism in human lung tissues and the effect of tobacco smoking: results from a case--control multicenter study on lung cancer patients. Environ Health Perspect (1992) 0.94
An unequal cross-over event within the CYP2D gene cluster generates a chimeric CYP2D7/CYP2D6 gene which is associated with the poor metabolizer phenotype. Br J Clin Pharmacol (1995) 0.93
Genetic predisposition to cancer. Br J Cancer (1991) 0.92
Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility. Environ Health Perspect (1992) 0.92
Susceptibility to multiple cutaneous basal cell carcinomas: significant interactions between glutathione S-transferase GSTM1 genotypes, skin type and male gender. Br J Cancer (1996) 0.91
A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol (2003) 0.90
Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease. J Neurol Neurosurg Psychiatry (1994) 0.89
Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: preliminary findings. J Int Neuropsychol Soc (2010) 0.88
Genes and cancer. Arch Dis Child (1999) 0.88
Expression and alternative splicing of the cytochrome P-450 CYP2A7. Biochem J (1995) 0.87
Association between genetic polymorphisms of the cytochromes P-450 (1A1, 2D6, and 2E1) and the susceptibility to pancreatic cancer. Korean J Intern Med (1997) 0.86
The influence of cytochrome P450 pharmacogenetics on disposition of common antidepressant and antipsychotic medications. Clin Biochem Rev (2006) 0.86
Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol. Biochem J (1996) 0.84
Identification of genetic variants of human cytochrome P450 2D6 with impaired mitochondrial targeting. Mol Genet Metab (2010) 0.84
Study of CYP2D6 gene in children with autoimmune hepatitis and P450 IID6 autoantibodies. Clin Exp Immunol (1992) 0.83
Pharmacogenetics: detecting sensitive populations. Environ Health Perspect (1994) 0.83
CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting. AAPS PharmSci (2000) 0.82
Cytochrome P4502D6 genotype does not determine response to clozapine. Br J Clin Pharmacol (1995) 0.82
Polymorphism in CYP1A1 and CYP2D6 genes: possible association with susceptibility to lung cancer. Environ Health Perspect (1993) 0.81
Long-Read Single Molecule Real-Time Full Gene Sequencing of Cytochrome P450-2D6. Hum Mutat (2015) 0.81
Progression of cervical intraepithelial neoplasia to cervical cancer: interactions of cytochrome P450 CYP2D6 EM and glutathione s-transferase GSTM1 null genotypes and cigarette smoking. Br J Cancer (1994) 0.80
Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population. Br J Clin Pharmacol (1993) 0.80
Lack of associations among cancer and albumin adducts, ras p21 oncoprotein levels, and CYP1A1, CYP2D6, NAT1, and NAT2 in a nested case-control study of lung cancer within the physicians' health study. Cancer Epidemiol Biomarkers Prev (2006) 0.80
Genotype and allele frequency of CYP2D6 in Tamilian population. Eur J Clin Pharmacol (2003) 0.78
Genetic polymorphisms of phase I and phase II metabolic enzymes as modulators of lung cancer susceptibility. J Cancer Res Clin Oncol (2014) 0.77
The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype. Environ Health Perspect (1992) 0.76
New nucleotide sequence data on the EMBL File Server. Nucleic Acids Res (1992) 0.75
The CYP2D6 VCF Translator. Pharmacogenomics J (2016) 0.75
New nucleotide sequence data on the EMBL File Server. Nucleic Acids Res (1991) 0.75
Pharmacogenetics and gender association with psychotic episodes on nortriptyline lower doses: patient cases. ISRN Pharm (2011) 0.75
Haloperidol plasma concentration in Japanese psychiatric subjects with gene duplication of CYP2D6. Br J Clin Pharmacol (2003) 0.75
Pharmacogenetics informed decision making in adolescent psychiatric treatment: a clinical case report. Int J Mol Sci (2015) 0.75
Umbilical cord blood transplantation. Arch Dis Child (1999) 0.75
Gene variants of CYP1A1 and CYP2D6 and the risk of childhood acute lymphoblastic leukaemia; outcome of a case control study from Kashmir, India. Mol Biol Res Commun (2017) 0.75
[Cytochrom-P450 mediated drug interactions caused by antibiotics]. Wien Med Wochenschr (2006) 0.75
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med (2001) 7.51
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature (1982) 5.95
Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A (2000) 5.89
Regulation of JNK signaling by GSTp. EMBO J (1999) 4.06
Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1. Nature (1983) 3.86
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol (1979) 3.78
Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine. Br J Cancer (2010) 3.25
Capturing genes encoding membrane and secreted proteins important for mouse development. Proc Natl Acad Sci U S A (1995) 3.16
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther (2011) 3.09
Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics (2001) 3.05
An autosomal transcript in skeletal muscle with homology to dystrophin. Nature (1989) 2.91
Regulated expression and phosphorylation of a possible mammalian cell-cycle control protein. Nature (1988) 2.88
Shigella-induced apoptosis is dependent on caspase-1 which binds to IpaB. J Biol Chem (1998) 2.75
Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem (2001) 2.62
Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther (2001) 2.62
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest (1999) 2.57
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther (2007) 2.48
The Nrf2 transcription factor contributes both to the basal expression of glutathione S-transferases in mouse liver and to their induction by the chemopreventive synthetic antioxidants, butylated hydroxyanisole and ethoxyquin. Biochem Soc Trans (2000) 2.40
Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther (2013) 2.38
Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases. Proc Natl Acad Sci U S A (1998) 2.32
Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther (2008) 2.31
Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther (1982) 2.26
Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet (1982) 2.19
Testicular degeneration in Bclw-deficient mice. Nat Genet (1998) 2.17
Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther (2007) 2.17
Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics (2001) 2.08
The teaching and organisation of clinical pharmacology in European medical schools (W.H.O. Working Group on Clinical Pharmacology). Eur J Clin Pharmacol (1990) 2.07
Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer (1998) 2.06
Single nucleotide polymorphisms as tools in human genetics. Hum Mol Genet (2000) 2.05
Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis (1997) 2.05
Chromosomal localisation of the human homologues to the oncogenes erbA and B. EMBO J (1984) 2.02
Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet (2001) 2.02
Linkage of an American pedigree with palmoplantar keratoderma and malignancy (palmoplantar ectodermal dysplasia type III) to 17q24. Literature survey and proposed updated classification of the keratodermas. Arch Dermatol (1996) 2.00
The human placental alkaline phosphatase gene and related sequences map to chromosome 2 band q37. Ann Hum Genet (1987) 2.00
Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther (2011) 1.98
Chromosomal localization of human cellular homologues of two viral oncogenes. Nature (1982) 1.96
Simple repeat sequences on the human Y chromosome are equally polymorphic as their autosomal counterparts. Hum Genet (1992) 1.94
Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91
Stable length polymorphism of up to 260 kb at the tip of the short arm of human chromosome 16. Cell (1991) 1.87
Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis (1993) 1.84
Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis (1997) 1.78
Plectin deficiency results in muscular dystrophy with epidermolysis bullosa. Nat Genet (1996) 1.78
Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem Pharmacol (1994) 1.76
The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut (2005) 1.73
A first-generation whole genome-radiation hybrid map spanning the mouse genome. Genome Res (1997) 1.73
Physiological disposition of verapamil in man. Cardiovasc Res (1976) 1.71
Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics (1996) 1.67
Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut (2003) 1.66
Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics (1998) 1.64
Chromosomal locations of the gene coding for the CD3 (T3) gamma subunit of the human and mouse CD3/T-cell antigen receptor complexes. Immunogenetics (1987) 1.60
Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol (1975) 1.60
Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet (1991) 1.60
Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos (2001) 1.58
Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol (1991) 1.57
Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res (1995) 1.57
Complete sequence of human vinculin and assignment of the gene to chromosome 10. Proc Natl Acad Sci U S A (1990) 1.57
Molecular mechanisms of drug resistance. Biochem J (1990) 1.56
Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways. J Pharmacol Exp Ther (2001) 1.56
Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur J Clin Pharmacol (1980) 1.55
Investigation of interaction between N-acetyltransferase 2 and heterocyclic amines as potential risk factors for colorectal cancer. Carcinogenesis (2003) 1.54
Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis (1991) 1.53
Polymorphic drug oxidation in humans. Fed Proc (1984) 1.53
Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain (1998) 1.52
Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. N Engl J Med (1989) 1.52
An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy. Circulation (1994) 1.52
Dissection of NADPH-cytochrome P450 oxidoreductase into distinct functional domains. Proc Natl Acad Sci U S A (1994) 1.51
The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics (2001) 1.50
Structural and functional relationships between fumarase and aspartase. Nucleotide sequences of the fumarase (fumC) and aspartase (aspA) genes of Escherichia coli K12. Biochem J (1986) 1.50
CYP2D6 genotyping and the association with lung cancer susceptibility. Pharmacogenetics (1994) 1.50
Alternative splicing in the human cytochrome P450IIB6 gene generates a high level of aberrant messages. Nucleic Acids Res (1989) 1.48
Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther (2000) 1.48
Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient. Int J Cancer (1987) 1.47
Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochenschr (1985) 1.46
Characterization and chromosomal assignment of a human cell surface antigen defined by the monoclonal antibody AUAI. Int J Cancer (1986) 1.45
Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects. Carcinogenesis (1988) 1.45
The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages. J Biol Chem (2001) 1.44
Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J (1992) 1.44
Amplification and increased expression of alpha class glutathione S-transferase-encoding genes associated with resistance to nitrogen mustards. Proc Natl Acad Sci U S A (1988) 1.43
Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology (1996) 1.42
Nucleotide sequence and transcriptional start point of the phosphomannose isomerase gene (manA) of Escherichia coli. Gene (1984) 1.41
Is there a genetic factor in flecainide toxicity? BMJ (1988) 1.41
Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet (1992) 1.41
The human IL-1 receptor antagonist gene (IL1RN) maps to chromosome 2q14-q21, in the region of the IL-1 alpha and IL-1 beta loci. Genomics (1992) 1.40
Increased resistance to acetaminophen hepatotoxicity in mice lacking glutathione S-transferase Pi. Proc Natl Acad Sci U S A (2000) 1.40
Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. Br J Clin Pharmacol (1984) 1.39
The metabolism of DL-[14C]verapamil in man. Drug Metab Dispos (1979) 1.39
The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol (1995) 1.39
Msp-1 polymorphism detected with a cDNA probe for the P-450 I family on chromosome 15. Nucleic Acids Res (1987) 1.37
The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. Am Heart J (1985) 1.35